Abstracts tagged "Osteoarthritis"

Abstract Number: 0943 • ACR Convergence 2021
Metabolomic Profiling of Synovial Tissue of Patients with Osteoarthritis
Jessica Murillo Saich¹, Roxana Coras², Robert Meyer³ and Monica Guma⁴, ¹University of California San Diego, La Jolla, CA, ²University of California San Diego/Department of Medicine, Autonomous University of Barcelona, San Diego, CA, ³San Diego VA Healthcare Service, La Jolla, CA, ⁴University of California San Diego/San Diego VA Healthcare Service/Department of Medicine, Autonomous University of Barcelona, La Jolla, CA
Background/Purpose: Increasing evidence indicates that osteoarthritis (OA) progression is mediated not simply by progressive degeneration of cartilage, but also by low-grade synovial inflammation (synovitis) that…
Abstract Number: 1123 • ACR Convergence 2021
“It’s a Dance Between Managing Both [Diabetes and Osteoarthritis]”: A Qualitative Study Exploring Perspectives of Persons with Knee Osteoarthritis and Type 2 Diabetes Mellitus on the Impact of Osteoarthritis on Diabetes Management and Daily Life
Lauren King¹, Esther Waugh¹, Crystal McKay¹, Ian Stanaitis² and Gillian Hawker¹, ¹University of Toronto, Toronto, ON, Canada, ²Women's College Hospital, Toronto, ON, Canada
Background/Purpose: The links between osteoarthritis (OA) and other common chronic conditions, such as type 2 diabetes mellitus (T2DM), are increasingly being appreciated in epidemiological studies.…
Abstract Number: 1468 • ACR Convergence 2021
Intra-articular (IA) Injection of Empty Large Multilamellar Vesicles Liposomes Reduces Cartilage Degeneration in Rat Osteoarthritis Model
Alison Bendele¹, Jacob Favret¹, Gadi Sarfati², Ronny Pinkus² and Roni Wechsler², ¹Bolder BioPATH Inc., Boulder, CO, ²Moebius Medical LTD, Tel Aviv, Israel
Background/Purpose: A suspension of empty large multilamellar vesicles (MLV) liposomes composed of dimyristoylphosphatidylcholine (DMPC) and dipalmitoylphosphatidylcholine (DPPC), is currently under clinical development for symptomatic knee…
Abstract Number: 0026 • ACR Convergence 2021
Synovial Fibroblasts Acquire a Proinflammatory and Destructive Phenotype After Exposure to αS1-Casein (CSN1S1)
Nadine Honke¹, Tim Appel¹, Matthias Schneider² and Georg Pongratz³, ¹Department of Rheumatology, Hiller Research Center Rheumatology, University Hospital Düsseldorf, Germany (* contributed equally), Düsseldorf, Germany, ²Policlinic & Hiller Research Unit Rheumatology, UKD, Heinrich-Heine University, Düsseldorf, Germany, ³Polyclinic and Functional Area for Rheumatology & Hiller Research Center Rheumatology, University Hospital Düsseldorf, Düsseldorf, Germany
Background/Purpose: The milk protein αS1-Casein (CSN1S1) was described to be overexpressed in synovial tissue of patients with rheumatoid arthritis (RA) and osteoarthritis (OA). Recently we…
Abstract Number: 0224 • ACR Convergence 2021
Effects of Kinesiophobia and Physical Function on Physical Activity in Adults with Knee Osteoarthritis
Burcu Aydemir and Kharma Foucher, University of Illinois at Chicago, Chicago, IL
Background/Purpose: Only a small proportion of people with knee osteoarthritis (OA) meet the recommended guidelines for physical activity and it is still unclear why. Lacking…
Abstract Number: 0727 • ACR Convergence 2021
Total Joint Replacements in Three Phase 3 Studies of Tanezumab in Patients with Osteoarthritis
John Carrino¹, Timothy McAlindon², Eric Vignon³, Mark Brown⁴, Aimee Burr⁴, Robert Fountaine⁴, Glenn Pixton⁵, Lars Viktrup⁶, Christine West⁴ and Kenneth Verburg⁴, ¹Hospital for Special Surgery, New York, NY, ²Tufts Medical Center, Arlington, MA, ³Université Claude Bernard Lyon 1, Lyon, France, ⁴Pfizer Inc., Groton, CT, ⁵Pfizer Inc., Morrisville, NC, ⁶Eli Lilly and Company, Indianapolis, IN
Background/Purpose: Tanezumab (TNZ) is an antibody against nerve growth factor that has demonstrated efficacy in the management of osteoarthritis (OA). Due to the potential risk…
Abstract Number: 1028 • ACR Convergence 2021
Knee Osteoarthritis and Mortality: The Osteoarthritic Initiative
Jane Cauley¹, Michael Nevitt², Kai Sun³, Jason Maeda³, C. Kent Kwoh⁴, Leena Sharma⁵, Rebecca Jackson⁶, Susan Rubin³ and Marc Hochberg⁷, ¹University of Pittsburgh Graduate School of Public Health, Pittsbugh, PA, ²University of California San Francisco, Orinda, CA, ³University of California San Francisco, San Francisco, CA, ⁴University of Arizona College of Medicine, Tuscon, AZ, ⁵Northwestern University, Chicago, IL, ⁶Ohio State University, Columbus, OH, ⁷University of Maryland School of Medicine, Baltimore, MD
Background/Purpose: A recent international individual participant data (IPD) meta-analysis (n=10,723) reported a 35-37% increased mortality risk among individuals with painful knees (no radiographic OA) and…
Abstract Number: 1124 • ACR Convergence 2021
Examining the Relationships Between Treatment and Pain and Physical Function Outcomes in Patients with Osteoarthritis: A Mediation Modeling Approach
Lucy Abraham¹, Robert Dworkin², Dennis C. Turk³, John D. Markman², David A. Williams⁴, Andrew G Bushmakin⁵, Jerry A. Hall⁶, David C. Semel⁷, Joseph C Cappelleri⁵ and Ruoyong Yang⁸, ¹Pfizer Ltd., Tadworth, United Kingdom, ²University of Rochester, Rochester, NY, ³University of Washington, Seattle, WA, ⁴University of Michigan, Ann Arbor, MI, ⁵Pfizer Inc, Groton, CT, ⁶Eli Lilly and Company, Indianapolis, IN, ⁷Pfizer, New York, NY, ⁸Pfizer Inc., New York, NY
Background/Purpose: To better understand the complex relationships between treatment and pain and physical function (PF) outcomes, we investigated a set of mediation models of osteoarthritis…
Abstract Number: 1470 • ACR Convergence 2021
Cartilage Epigenetic Changes Induced by Microbial DNA Amplified from Human OA Samples
Vladislav Izda¹, Christopher Dunn², Cassandra Sturdy¹, Jake Martin¹, Cassandra Velasco², Paul Jacob³ and Matlock Jeffries¹, ¹Oklahoma Medical Research Foundation, Oklahoma City, OK, ²University of Oklahoma Health Sciences Center, Oklahoma City, OK, ³Oklahoma Joint Reconstruction Institute, Oklahoma City, OK
Background/Purpose: Strong links between epigenetic changes, particularly alterations in DNA methylation, have been linked with the onset and progression of knee osteoarthritis (OA); however, the…
Abstract Number: 0051 • ACR Convergence 2021
Identification of Biomarkers and Deregulated Pathways in Psoriatic Arthritis Through Proteomic Analysis of Synovial Fluid
Jacqueline Lai¹, Sara Rahmati², Raam Sivakumar², Katerina Oikonomopoulou³, Fatima Abji⁴ and Vinod Chandran⁵, ¹McMaster University, Hamilton, ON, Canada, ²University Health Network, Toronto, ON, Canada, ³Krembil Research Institute, Toronto, ON, Canada, ⁴University of Toronto, University Health Network, Toronto, ON, Canada, ⁵Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Psoriatic arthritis (PsA) is an inflammatory arthritis that currently lacks diagnostic biomarkers. We hypothesized that there are differences in the protein intensities in the…
Abstract Number: 0465 • ACR Convergence 2021
Cost-effectiveness of Treatment Strategies Involving Arthroscopic Partial Meniscectomy and Physical Therapy for Degenerative Meniscal Tear
Emma Williams¹, Valia Leifer¹, Jamie Collins², Tuhina Neogi³, Lisa Suter⁴, Jeffrey Katz⁵ and Elena Losina², ¹The Orthopaedic and Arthritis Center for Outcomes Research (OrACORe) at Brigham and Women's Hospital, Boston, MA, ²Brigham and Women's Hospital, Boston, MA, ³Boston University School of Medicine, Boston, MA, ⁴Yale School of Medicine, New Haven, CT, ⁵Brigham and Women's Hospital, Brookline, MA
Background/Purpose: Knee osteoarthritis (KOA) and meniscal tear (MT) are highly prevalent and often concomitant. Treatments for MT in the presence of KOA include physical therapy…
Abstract Number: 0728 • ACR Convergence 2021
Intra-articular Canakinumab (anti-interleukin-1β) for Treatment of Symptomatic Knee Osteoarthritis: A Randomized, Double-blind, Placebo and Naproxen-controlled Phase II Study
Philip Conaghan¹, Xavier Chevalier², Linda Mindeholm³, Ursula Schramm³, Jens Praestgaard³, Abdelkader Seroutou³, Ronenn Roubenoff³ and Matthias Schieker³, ¹Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ²Henri Mondor University Hospital and Paris University XII, UPEC, Créteil, France, Créteil, France, ³Novartis Institutes for Biomedical Research, Basel, Switzerland, Basel, Switzerland
Background/Purpose: Knee osteoarthritis (OA) is a common musculoskeletal disease associated with pain and functional impairment. There are few effective therapies, often limited by side-effects.1 This…
Abstract Number: 1035 • ACR Convergence 2021
The ELSA-Brasil Musculoskeletal Cohort (ELSA-Brasil MSK): Design, Implementation and Prevalence of Chronic Musculoskeletal Pain and Radiographic Knee Osteoarthritis at Baseline
Rosa Weiss Telles¹, Luciana Machado², Luciana Costa-Silva³ and Sandhi Maria Barreto¹, ¹Universidade Federal de Minas Gerais, Belo Horizonte, Brazil, ²Clinical Hospital, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil, ³Instituto Hermes Pardini. Hospital das Clínicas, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil
Background/Purpose: Musculoskeletal (MSK) disorders, including low back pain and osteoarthritis (OA), are ranked among the top causes of years lived with disability and increased risk-attributable…
Abstract Number: 1125 • ACR Convergence 2021
Synovial Perivascular Edema Is Associated with Altered Knee Loading Patterns During Gait in Patients with Medial Compartment-Dominant Knee Osteoarthritis
McKenzie Carter¹, Holly Philpott¹, Trevor Birmingham², Ryan Pinto³, Codie Primeau¹, J. Robert Giffin¹, Brent Lanting² and Tom Appleton², ¹Western University, London, ON, Canada, ²University of Western Ontario, London, ON, Canada, ³Western University, Kitchener, ON, Canada
Background/Purpose: Synovial inflammation and aberrant joint loads are independent risk factors for knee osteoarthritis (OA) incidence and progression. Perivascular edema, the accumulation of fluid around…
Abstract Number: 1471 • ACR Convergence 2021
Oral Administration of Berberine Limits Post-traumatic Osteoarthritis Development and Associated Pain via AMP-activated Protein Kinase (AMPK) in Mice
Jun Li¹, Yun Wang², Di Chen³ and Ru Liu Bryan⁴, ¹Rush University Medical Center, Chicago, IL, ²Valo Health, Lexington, MA, ³Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen, China (People's Republic), ⁴University of California San Diego and VASDHS, San Diego, CA
Background/Purpose: AMP-activated protein kinase (AMPK), a master regulator of energy balance and metabolism, is implicated to play an important role in cartilage homeostasis. Berberine is…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].